Rallybio Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Rallybio hat ein Gesamteigenkapital von $80.0M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $92.4M bzw. $12.4M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$88.61m
Eigenkapital	US$80.02m
Gesamtverbindlichkeiten	US$12.41m
Gesamtvermögen	US$92.43m

Jüngste Berichte zur Finanzlage

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

May 15

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Jan 30

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Oct 31

Recent updates

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Aug 28

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Jan 04

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Sep 19

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

May 15

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Jan 30

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Oct 31

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Jul 07

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

Mar 16

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: RLYBDie kurzfristigen Aktiva des Unternehmens ($91.4M) übersteigen seine kurzfristigen Passiva ($12.2M).

Langfristige Verbindlichkeiten: RLYBDie kurzfristigen Vermögenswerte des Unternehmens ($91.4M) übersteigen seine langfristigen Verbindlichkeiten ($253.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: RLYB ist schuldenfrei.

Schulden abbauen: RLYB hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: RLYB auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: RLYB über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt, wenn der freie Cashflow weiterhin mit historischen Raten von 22.1% pro Jahr zurückgeht

Rallybio Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Recent updates

Rallybio Announces Publication of RLYB212 Phase 1 Proof-Of-Concept Study Results in Thrombosis and Haemostasis

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Price target decreased by 19% to US$10.50

Rallybio Corporation(NasdaqGS:RLYB) dropped from Russell 3000 Index

Rallybio Corporation Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Rlybocytopenia

Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio Corporation, Annual General Meeting, May 15, 2024

Rallybio Corporation announced that it has received $6.599999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.38

Rallybio Corporation Announces the Prioritization of Its Portfolio and a 45% Workforce Reduction to Focus Resources on Its Phase 2-Ready Clinical Stage Programs

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Rallybio Corporation Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116

Rallybio Corporation Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212

New major risk - Share price stability

New minor risk - Market cap size

Rallybio Corporation Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Rallybio Corporation Presents Phase 1 Single Ascending Dose Data for RLYB116, Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Price target decreased by 7.3% to US$16.83

Rallybio Corporation Announces Executive Changes

Rallybio Corporation Reports Data from the Phase 1b Proof-Of-Concept Study of RLYB212

Price target decreased by 9.9% to US$18.17

Rallybio to Present Data from the RLYB212 Phase 1b Proof-Of-Concept Study

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Price target decreased by 7.2% to US$22.50

Rallybio Corporation Announces Chief Financial Officer Changes

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Rallybio Announces Publication of Data Highlighting the Ability of HPA-1A-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT

Price target decreased to US$28.00

High number of new directors

Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Price target increased to US$30.67

Rallybio Corporation Expects to Discuss the Preliminary Platelet Elimination Data by the End of the Third Quarter of 2022

Rallybio Corporation Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Corporation Announces Retirement of Jeffrey Fryer as Chief Financial Officer

High number of new directors

Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

High number of new directors

Rallybio Corporation, Annual General Meeting, May 24, 2022

High number of new directors

Rallybio Corporation Announces Board Changes

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

CEO & Chairman recently bought US$103k worth of stock

High number of new directors

Rallybio Corporation Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen